Year archive

Abliva — 2015 filings

All 68 regulatory filings released by Abliva (ABLI) in 2015, sourced directly from the official regulator.

68 Filings

2015 Period

2015 filings (68)

Filing	Released	Lang
NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study Legal Proceedings Report	2015-11-19	English
NeuroVive rapporterar positiv säkerhetsutvärdering av fas II-studie för skydd mot akut njurskada Regulatory Filings	2015-11-19	Swedish
Earnings Release 2015 Earnings Release 9M 2015	2015-11-18	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-11-18	English
NeuroVive presenterar forskningsresultat vid World Mitochondria Congress Regulatory Filings	2015-11-02	Swedish
NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress Regulatory Filings	2015-11-02	English
NeuroVive siktar på att hitta en väg framåt för bolagets antivirala utveckling efter Arbutus beslut att avsluta preklinisk utveckling av OCB-030 Legal Proceedings Report	2015-10-28	Swedish
NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus Regulatory Filings	2015-10-28	English
NeuroVive stärker sitt team för klinisk utveckling - tillsätter doktor Magnus Hansson som Chief Medical Officer Board/Management Information	2015-10-23	Swedish
NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer Board/Management Information	2015-10-23	English
Årsstämma 2016 och valberedningen Report Publication Announcement	2015-10-16	Swedish
Annual General Meeting 2016 and Nomination Committee AGM Information	2015-10-16	English
NeuroVive meddelar att VD lämnar bolaget – Jan Nilsson tar över som tf VD Board/Management Information	2015-09-01	Swedish
NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO Board/Management Information	2015-09-01	English
NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication Regulatory Filings	2015-08-31	English
NeuroVive ändrar inriktning för CicloMulsion – avslutar läkemedelsutvecklingen mot akut hjärtinfarkt Regulatory Filings	2015-08-31	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2015-08-19	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report H2 2015	2015-08-19	English
NeuroVive share upgraded on OTC market in US Regulatory Filings	2015-06-26	English
NeuroVives aktie uppgraderad på OTC-marknaden i USA Regulatory Filings	2015-06-26	Swedish
NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction Legal Proceedings Report	2015-06-01	English
NeuroVive meddelar topline-resultat från fas III-studien (CIRCUS) med CicloMulsion® för behandling av akut hjärtinfarkt Earnings Release Q2 2015	2015-06-01	Swedish
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ) Declaration of Voting Results & Voting Rights Announcements	2015-05-29	Swedish
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes Declaration of Voting Results & Voting Rights Announcements	2015-05-29	English
Aktieförsäljning utanför marknaden efter genomförda aktieinbyten Director's Dealing	2015-05-26	Swedish
Sale of shares off the market following share exchange program Share Issue/Capital Change	2015-05-26	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-05-25	English
Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter Earnings Release Q2 2015	2015-05-25	English
Topline-resultat från fas III-studien med CicloMulsion® för behandling efter hjärtinfarkt förväntas under innevarande kvartal Regulatory Filings	2015-05-25	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-20	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-20	English
NeuroVive offentliggör prospekt avseende upptagande till handel av nya aktier Capital/Financing Update	2015-05-18	Swedish
NeuroVive announces prospectus regarding admission to trading of new shares Share Issue/Capital Change	2015-05-18	English
Declaration of Voting Results & Voting Rights Announcements 2015 Declaration of Voting Results & Voting Rights Announcements	2015-05-11	English
NeuroVive genomför riktad nyemission och tillförs 70 MSEK för att förbereda klinisk prövning av CicloMulsion® i USA och marknadslansering i Europa Capital/Financing Update	2015-05-08	Swedish
NeuroVive completes share issue raising SEK 70 million for the preparation of CicloMulsion®’s clinical trial in the US and commercialization in Europe Share Issue/Capital Change	2015-05-08	English
NeuroVive planerar genomföra en riktad nyemission Capital/Financing Update	2015-05-07	Swedish
NeuroVive announces the intention to raise additional capital through a private placement Share Issue/Capital Change	2015-05-07	English
Första patienten inkluderad i fas II-studie för skydd mot akut njurskada vid hjärtoperation Regulatory Filings	2015-04-27	Swedish
First patient enrolled in clinical phase II study for kidney protection during heart surgery Regulatory Filings	2015-04-27	English
Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation Regulatory Filings	2015-04-21	English
Klinisk fas II-studie med NeuroSTAT® för traumatisk hjärnskada passerar säkerhetsutvärdering Regulatory Filings	2015-04-21	Swedish
NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL Regulatory Filings	2015-04-20	English
NeuroVive etablerar dotterbolag i Lyon och breddar samarbetet med HCL Regulatory Filings	2015-04-20	Swedish
Utvecklingen av NVP014 för strokebehandling går in i ny fas tillsammans med Isomerase Therapeutics Regulatory Filings	2015-04-17	Swedish
Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics Regulatory Filings	2015-04-17	English
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes Declaration of Voting Results & Voting Rights Announcements	2015-03-31	English
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ) Declaration of Voting Results & Voting Rights Announcements	2015-03-31	Swedish
NeuroVive Pharmaceutical AB (publ): kommuniké från årsstämma AGM Information	2015-03-30	Swedish
NeuroVive Pharmaceutical AB (publ): report from AGM AGM Information	2015-03-30	English
Report Publication Announcement 2015 Report Publication Announcement	2015-03-18	English
Report Publication Announcement 2015 Report Publication Announcement	2015-03-06	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-03-04	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-02-25	English
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ) AGM Information	2015-02-25	English
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ) AGM Information	2015-02-25	Swedish
NeuroVive genomför riktad nyemission om 65 MSEK för fortsatt expansion Capital/Financing Update	2015-02-20	Swedish
NeuroVive completes a directed share issue of SEK 65 million for continued expansion Capital/Financing Update	2015-02-20	English
Earnings Release 2014 Earnings Release Q4 2014	2015-02-18	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report FY 2014	2015-02-18	English
Nyetablerat dotterbolag erhåller finansiering om drygt 3 miljoner USD inför potentiell notering i Taiwan Share Issue/Capital Change	2015-02-11	Swedish
New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan Regulatory Filings	2015-02-11	English
OnCore Biopharma and Tekmira Pharmaceuticals files for merger – releases further details about license agreement with NeuroVive M&A Activity	2015-02-05	English
OnCore Biopharma och Tekmira Pharmaceuticals siktar mot samgående – offentliggör ytterligare information om licensavtalet med NeuroVive Regulatory Filings	2015-02-05	Swedish
Samgåendet mellan OnCore och Tekmira inkluderar utvecklingen av NVP018 inom hepatit B-behandling M&A Activity	2015-01-19	Swedish
Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B Regulatory Filings	2015-01-19	English
Årsstämman tidigareläggs till den 30 mars 2015 AGM Information	2015-01-12	Swedish
Annual General Meeting brought forward to March 30 2015 Report Publication Announcement	2015-01-12	English

Filings by year

2025 11 filings
2024 38 filings
2023 23 filings
2022 38 filings
2021 40 filings
2020 43 filings
2019 45 filings
2018 57 filings
2017 63 filings
2016 72 filings
2015 68 filings
2014 61 filings
2013 35 filings